New study aims to use PET scans to spot Non-Responders early in HER2 low breast cancer
NCT ID NCT07130344
First seen Sep 30, 2025 · Last updated Apr 30, 2026 · Updated 28 times
Summary
This study looks at whether a special type of PET scan can detect if the drug trastuzumab deruxtecan is working earlier than standard CT scans in people with HER2 low breast cancer that has spread. About 262 participants will be followed to compare PET and CT results. The goal is to avoid giving an expensive and toxic treatment to those who won't benefit, improving their quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ICANS
Strasbourg, 67033, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.